What is microdosing tirzepatide?

Taking less than the standard schedule calls for — usually staying at 2.5 mg indefinitely, drawing a partial dose, splitting a weekly dose in two, or extending the interval between doses. The term has no clinical definition, so two people describing it may be doing quite different things.

Is there any research on microdosing tirzepatide?

No. SURMOUNT-1 tested 5 mg, 10 mg and 15 mg once weekly; 2.5 mg appears only as a four-week initiation step, never as a studied maintenance dose. There is no trial estimate for a year at 2.5 mg, for sub-2.5 mg doses, or for extended intervals. Percentages quoted for microdosing come from different regimens.

Does a lower tirzepatide dose still work?

Within the studied range, a lot of it does. In SURMOUNT-1, 5 mg produced 15.0% average weight reduction against 20.9% at 15 mg, while gastrointestinal adverse events ran 39% versus 49%. Choosing 5 mg is not microdosing — it is dosing at the low end of a range that was actually studied.

Is splitting a tirzepatide dose into two injections a good idea?

It redistributes rather than reduces. With a half-life near five days, splitting lowers the peak concentration and raises the trough without changing average exposure. Some people find that easier on the stomach, which is plausible since side effects track the post-injection peak, but it is not a dose reduction and it has not been studied.

Can I take tirzepatide every two weeks instead of weekly?

Extending the interval lets blood levels fall substantially between doses, which can reintroduce escalation-phase side effects each time you dose — the difficulty of the first weeks, repeated indefinitely. It has not been studied, and it works against the pharmacology that makes weekly dosing steady.

What is the actual risk of microdosing tirzepatide?

Usually the measurement, not the dose. Compounded vials are prepared at a concentration the pharmacy sets and dosed in units of volume, so drawing 'half' without confirming concentration is a guess. Repeatedly entering a vial also raises contamination risk and shortens usable life. A prescriber can simply write a low dose instead.

Microdosing Tirzepatide: What It Means

Microdosing tirzepatide generally means taking less than the standard schedule calls for — staying at 2.5 mg indefinitely, or splitting a dose into smaller weekly or twice-weekly amounts. It has no clinical definition and no trial has tested it. Everything claimed about it is extrapolation from data collected at higher doses.

That is worth saying plainly before anything else, because the term is used online as though it referred to an established protocol. It does not.

What microdosing tirzepatide means in practice

There is no agreed definition, which is the first practical problem — two people describing their microdosing routine may be doing quite different things. In practice it usually refers to one of:

Staying at the 2.5 mg starting dose rather than escalating.
Sitting below 2.5 mg by drawing a partial dose from a compounded vial.
Splitting a weekly dose into two smaller injections across the week.
Extending the interval — dosing every ten days or every two weeks instead of weekly.

The motivations are consistent and reasonable: side effects, cost, a wish to maintain rather than keep losing, or a belief that a smaller dose gives most of the benefit with less of the burden.

What the evidence does and does not cover

The trials tested a specific ladder. In SURMOUNT-1, 2,539 adults took 5 mg, 10 mg or 15 mg once weekly for 72 weeks, producing average weight reductions of 15.0%, 19.5% and 20.9% against 3.1% on placebo (Jastreboff et al., NEJM 2022). The 2.5 mg dose appears in that programme only as a four-week initiation step, not as a maintenance dose anyone was studied on long-term.

So there is no trial estimate of what a year at 2.5 mg does, and none at all for sub-2.5 mg or extended intervals. Anyone quoting a percentage for microdosing is quoting a number that was measured on a different regimen.

What the data does show is a flattening curve. Going from 5 mg to 10 mg added about 4.5 percentage points of weight reduction; 10 mg to 15 mg added about 1.4. Meanwhile gastrointestinal adverse events climbed from 39% at 5 mg to 49% at 15 mg, and discontinuation for adverse events reached about 10% at the top dose (Mishra et al., J Endocr Soc 2023).

That shape is the strongest honest argument in the vicinity of microdosing: more is not proportionally better, and less is not proportionally worse. It is an argument for a lower dose, not evidence for a microdose.

The pharmacology problem with splitting and spacing

Tirzepatide's half-life is about five days, which is what makes weekly dosing work — levels stay reasonably steady between injections.

Splitting a weekly dose into two smaller ones does not lower your average exposure; it lowers the peak and raises the trough. Some people find that easier on the stomach, which is plausible given that side effects track the post-injection peak. It is a redistribution, not a reduction.

Extending the interval is the opposite. Dosing every two weeks lets levels fall substantially between doses, which can reintroduce the escalation-phase side effects each time you dose — the pattern that makes the first weeks hard, repeated indefinitely.

The better-supported version of what microdosers want

If the goal is fewer side effects, there is a strategy with direct evidence behind it: slow the titration. In a 2025 randomized pilot on the closely related GLP-1 semaglutide, gradual flexible titration cut gastrointestinal-related withdrawals from 19% to 2% and nausea from 64.2% to 45.1% versus the standard schedule, without compromising outcomes (Eldor et al., Diabetes Care 2025; a published correction was issued in February 2026).

If the goal is a sustainable long-term dose, settling at a studied maintenance dose is the evidenced path. 5 mg is a recognised maintenance dose and produced 15.0% average weight reduction in SURMOUNT-1 — most of what 15 mg delivered, at 39% versus 49% GI adverse events. Choosing 5 mg over 15 mg is not microdosing. It is dosing, at the low end of a range that was actually studied.

If the goal is cost, the honest fix is the price rather than the pharmacology. Our tirzepatide cost breakdown compares the routes; on a flat monthly plan, stretching a vial does not save money anyway.

Where the real risk sits

The risk in microdosing is rarely the small dose itself. It is the do-it-yourself measurement.

Compounded vials are prepared at a concentration the pharmacy sets, and instructions are often written in units on an insulin syringe. Units measure volume, not drug — so drawing "half" from a vial whose concentration you have not confirmed is a guess dressed as arithmetic. Repeatedly entering a vial to take partial doses also raises contamination risk and shortens how long the contents stay usable. See tirzepatide dosage and the titration ladder for how the standard progression is meant to work.

None of that is an argument against a low dose. It is an argument against improvising one without telling anyone.

What to do instead of quietly microdosing

A prescriber can write a low dose. That is an ordinary clinical decision, and holding someone at 2.5 mg or moving them back down is a normal response to side effects or to a maintenance goal. The difference between that and self-directed microdosing is that one is documented, monitored and adjustable, and the other is invisible to the person responsible for your care.

Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here — tirzepatide with vitamin B12 — is not FDA-approved. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality. A licensed provider reviews every request, sets the dose, and prescribes only when tirzepatide is appropriate for you — or declines. Not everyone qualifies, and follow-up check-ins are where the dose gets revisited.

If side effects or cost are pushing you toward taking less, that is exactly the conversation to bring to them. It is a request they can act on, and acting on it produces a plan rather than a workaround.